Related references
Note: Only part of the references are listed.Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors
Anthony S. Stein et al.
ANNALS OF HEMATOLOGY (2019)
Blinatumomab Pharmacodynamics and Exposure-Response Relationships in Relapsed/Refractory Acute Lymphoblastic Leukemia
Min Zhu et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Advances in adult acute lymphoblastic leukemia therapy
Ibrahim Aldoss et al.
LEUKEMIA & LYMPHOMA (2018)
Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia
Guoqing Wei et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL
Virginie Naegele et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2017)
Blinatumomab, a Bispecific T-cell Engager (BiTE®) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications
Min Zhu et al.
CLINICAL PHARMACOKINETICS (2016)
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
Max S. Topp et al.
LANCET ONCOLOGY (2015)
Allogeneic Hematopoietic Cell Transplantation in Adult Patients with Acute Lymphoblastic Leukemia
David I. Marks et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2014)
Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation
Nicola Goekbuget et al.
BLOOD (2012)
Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia
Pier Paolo Piccaluga et al.
LEUKEMIA & LYMPHOMA (2011)
Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases
Sara Raponi et al.
LEUKEMIA & LYMPHOMA (2011)
Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group
Albert Oriol et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Outcome of Adults With Acute Lymphocytic Leukemia After Second Salvage Therapy
Susan O'Brien et al.
CANCER (2008)
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody
Ralf Bargou et al.
SCIENCE (2008)
Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data
V. H. J. van der Velden et al.
LEUKEMIA (2007)
Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct
A Löffler et al.
LEUKEMIA (2003)
Share Paper
